相关实验视频

Updated: Jun 27, 2025

Observational Study Protocol for Repeated Clinical Examination and Critical Care Ultrasonography Within the Simple Intensive Care Studies

Observational Study Protocol for Repeated Clinical Examination and Critical Care Ultrasonography Within the Simple Intensive Care Studies

Published on: January 16, 2019

蛋白-S-100-β在接受ICU治疗的缺乏补偿性肝硬化患者中增加

Nicolas Weiss^1,2,3, Simona Tripon^1,2,4, Maxime Mallet^2,4

¹Sorbonne Université, AP-HP.Sorbonne Université, Hôpital de la Pitié-Salpêtrière, Département de Neurologie, Unité de Médecine Intensive Réanimation à Orientation Neurologique, Paris, France.

Journal of intensive medicine

|April 29, 2024

概括

患有不补偿性肝硬化症的重症监护室 (ICU) 患者中蛋白质S-100β (PS100-β) 水平升高表明血脑屏障 (BBB) 透性增加. 较高的PS100-Beta水平与明显的肝脑病变 (HE) 和较差的患者结局相关.

科学领域:

神经科学和神经病学神经科学和神经病学
肝病学和胃肠道学
关键护理医学关键护理医学

背景情况:

肝发性脑病 (HE) 是肝病的常见并发症,与高血和炎症有关.
改变血脑屏障 (BBB) 功能与HE病理生理学有关.
评估BBB完整性在临床上具有挑战性;蛋白S-100β (PS100β) 是BBB透性的潜在外围标记物.

研究的目的:

在重症监护室 (ICU) 检查非补偿性肝硬化患者的血PS100-Beta水平.
评估PS100-Beta水平与明显的HE存在之间的相关性.
评估PS100-Beta作为患者结果的预后标志物.

主要方法:

对一个前性队列的回顾性分析肝硬化ICU患者与PS100-Beta测量.
与门诊肝硬化和非肝硬化对照组进行比较.
用多变量逻辑回归和卡普兰-梅尔生存分析来评估预测价值和结果.

主要成果:

患有不补偿性肝硬化症的ICU患者的PS100-Beta水平明显高于门诊患者.
与非HEICU患者相比,开放式HE患者的PS100-Beta水平升高 (P=0.003).
PS100-Beta水平与Child-Pugh,MELD,C反应蛋白和氨血病相关;水平<0.12 mg/L预测了更好的生存率.

结论:

在非补偿性肝硬化 ICU 患者的血清 PS100-Beta 水平升高表明 BBB 透性增加.
较高的PS100-Beta水平与明显的HE有关,并与患者不良结果相关.
PS100-Beta显示出作为BBB功能障碍和HE预后的生物标志物的潜力.

关键词:

血脑屏障血脑屏障血脑屏障血脑屏障肝硬化是肝硬化的一种.肝脏脑病变肝脏脑病变是一种肝脏脑病变.肝脏疾病是一种肝脏疾病.在PS100-Beta中使用.

更多相关视频

Identification and Quantification of Deranged Metabolites in Critically Ill Patients Using NMR-Based Metabolomics

Identification and Quantification of Deranged Metabolites in Critically Ill Patients Using NMR-Based Metabolomics

Published on: November 29, 2024

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen

Published on: November 27, 2019

相关概念视频

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...